{
    "nct_id": "NCT04157985",
    "official_title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
    "inclusion_criteria": "* All patients must have an advanced solid tumor malignancy (specifically NSCLC, bladder, HNSCC, renal, melanoma, cervical, Merkel cell, MMR/MSI [colon, rectal, cholangio, esophageal, ovarian, uterine], anal, gastric and GE junction, hepatocellular, triple negative breast cancer) that is being treated with a PD-1/PD-L1 inhibitor including pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab according to standard of care treatment.\n* Patients who initially started treatment with another agent in combination with the PD-1/PD-L1 inhibitor, i.e. chemotherapy, ipilumumab, are eligible.\n* Patients must have at least stable disease as evidenced by scans performed within 6 weeks of randomization.\n* Signed Informed consent allowing randomization to stopping immunotherapy at 1 year Â± 6 weeks versus continued treatment beyond 1 year.\n* Patients can have measurable or non-measurable disease per RECIST v1.1.\n* Patients cannot be enrolled in a clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with documented progressive disease prior to randomization.\n* Patients with an immune-related toxicity preventing the continuation of treatment beyond 1 year at the treating physician's discretion.",
    "miscellaneous_criteria": ""
}